ANAB Stock: Price, Earnings History and SEC Filings
AnaptysBio, Inc. (ANAB) last traded at $48.28, down 0.74% on the latest session and down 3.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.11 against an analyst estimate of $-0.46, a beat of 76.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ANAB earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Sep 21, 2026 | $-0.11 | $-0.46 | +76.09% |
| Mar 2026 | May 12, 2026 | $-1.84 | $-0.32 | -475.00% |
| Dec 2025 | Mar 3, 2026 | $1.58 | $0.89 | +77.53% |
| Sep 2025 | Nov 4, 2025 | $0.52 | $-1.06 | +149.06% |
ANAB beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How ANAB reacts to earnings
Across its last 8 earnings releases, ANAB moved 7.4% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-05-12 | After close | -4.41% |
| 2026-03-03 | After close | +14.61% |
| 2026-01-09 | After close | +9.76% |
| 2025-11-04 | After close | +3.63% |
| 2025-08-06 | After close | -9.63% |
| 2025-05-05 | After close | -2.94% |
| 2025-02-27 | After close | +2.56% |
| 2024-11-05 | After close | +11.72% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ANAB financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $235M | -$13M | $20M | -5.6% | $-0.44 |
| 2024 | $91M | -$145M | -$136M | -159.1% | $-4.92 |
| 2023 | $17M | -$164M | -$122M | -953.7% | $-6.08 |
| 2022 | $10M | -$129M | -$74M | -1251.3% | $-4.57 |
| 2021 | $63M | -$58M | -$47M | -91.5% | $-2.11 |
| 2020 | $75M | -$20M | -$15M | -26.6% | $-0.73 |
| 2019 | $8M | -$97M | -$70M | -1216.7% | $-3.60 |
| 2018 | $5M | -$62M | -$50M | -1233.1% | $-2.50 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ANAB
- 8-K · Sep 21, 2026Financial statements and exhibits
- 8-K · Aug 11, 2026Shareholder vote, Financial statements and exhibits
- 8-K · Jul 30, 2026Regulation FD disclosure
- DEF 14A · Jun 29, 2026
- 8-K · Jun 22, 2026Material agreement
- 8-K · May 29, 2026Regulation FD disclosure
- 8-K · May 21, 2026Bylaw change
- 10-Q · May 12, 2026
- 8-K · May 12, 2026Results of operations, Financial statements and exhibits
- 8-K · May 11, 2026Officer or director change
Insider filing activity
ANAB insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ANAB news
- AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?Oct 31, 2026 · finance.yahoo.com
- Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?Oct 30, 2026 · finance.yahoo.com
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthOct 28, 2026 · finance.yahoo.com
- AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?Oct 27, 2026 · finance.yahoo.com
- Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerOct 19, 2026 · finance.yahoo.com
About AnaptysBio, Inc.
AnaptysBio, Inc. (ANAB) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in June.